Lee Hyukmin, Roh Kyung Ho, Hong Seong Geun, Shin Hee Bong, Jeong Seok Hoon, Song Wonkeun, Uh Young, Yong Dongeun, Lee Kyungwon
Department of Laboratory Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
Seegene Institute of Life Sciences, Seoul, Korea.
Ann Lab Med. 2016 Mar;36(2):138-44. doi: 10.3343/alm.2016.36.2.138.
Extensively drug-resistant (XDR) Pseudomonas aeruginosa and Acinetobacter baumannii are a threat to hospitalized patients. We evaluated the effects of antimicrobial combinations on XDR P. aeruginosa and A. baumannii isolates.
P. aeruginosa and A. baumannii isolates, which were resistant to all antibiotics except colistin (CL), were collected from eight hospitals in Korea. Genes encoding metallo-β-lactamases (MBLs) and OXA carbapenemases were detected by PCR in eight P. aeruginosa and 30 A. baumannii isolates. In vitro synergy of antimicrobial combinations was tested by using the checkerboard method.
Minimum inhibitory concentrations of β-lactams, aminoglycosides, and fluoroquinolones were very high, while that of CL was low for majority of XDR P. aeruginosa and A. baumannii isolates. Antimicrobial combinations including Imipenem (IPM)-CL, ceftazidime (CAZ)-CL, and rifampin (RIF)-CL exerted only additive/indifferent effects on majority of XDR P. aeruginosa isolates. Proportions of XDR A. baumannii isolates that showed synergistic and additive/indifferent inhibition after treatment with antimicrobial combinations used are as follows: IPM-ampicillin-sulbactam (AMS), 17% and 80% isolates, respectively; IPM-rifampin (RIF), 13% and 81% isolates, respectively; IPM-CL, 13% and 87% isolates, respectively; and RIF-COL, 20% and 73% isolates, respectively. Significant proportion (19%) of XDR P. aeruginosa isolates produced MBLs, and majority (82%) of A. baumannii isolates produced either MBLs or OXA-23.
Our results suggest that combinations of IPM-AMS, IPM-RIF, IPM-CL, and RIF-CL are more useful than individual drugs for treating 13-20% of XDR A. baumannii infections.
广泛耐药(XDR)铜绿假单胞菌和鲍曼不动杆菌对住院患者构成威胁。我们评估了抗菌药物联合使用对XDR铜绿假单胞菌和鲍曼不动杆菌分离株的影响。
从韩国的八家医院收集了对除黏菌素(CL)外所有抗生素均耐药的铜绿假单胞菌和鲍曼不动杆菌分离株。通过PCR检测了8株铜绿假单胞菌和30株鲍曼不动杆菌分离株中编码金属β-内酰胺酶(MBLs)和OXA碳青霉烯酶的基因。采用棋盘法测试抗菌药物联合使用的体外协同作用。
对于大多数XDR铜绿假单胞菌和鲍曼不动杆菌分离株,β-内酰胺类、氨基糖苷类和氟喹诺酮类的最低抑菌浓度非常高,而CL的最低抑菌浓度较低。包括亚胺培南(IPM)-CL、头孢他啶(CAZ)-CL和利福平(RIF)-CL在内的抗菌药物联合使用对大多数XDR铜绿假单胞菌分离株仅产生相加/无作用效果。使用抗菌药物联合治疗后,显示协同和相加/无作用抑制的XDR鲍曼不动杆菌分离株比例如下:IPM-氨苄西林-舒巴坦(AMS),分别为17%和80%的分离株;IPM-利福平(RIF),分别为13%和81%的分离株;IPM-CL,分别为13%和87%的分离株;以及RIF-COL,分别为20%和73%的分离株。相当比例(19%)的XDR铜绿假单胞菌分离株产生MBLs,大多数(82%)的鲍曼不动杆菌分离株产生MBLs或OXA-23。
我们的结果表明,对于治疗13%-20%的XDR鲍曼不动杆菌感染,IPM-AMS、IPM-RIF、IPM-CL和RIF-CL联合使用比单一药物更有效。